Please assess the completion status of the following clinical trial:

Trial Title: Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Life expectancy of at least 3 months~* ECOG performance status of 0 to 1~  • In sexually-active patients, willingness to use 2 effective methods of contraception~* Adequate hematological and organ function, confirmed by lab values~* Tumor tissue must be available for prospective determination of FGFR2b overexpression~  * Locally recurrent or metastatic disease that has progressed on or following standard treatment, or is not a candidate for standard treatment~ * Histologically or cytologically confirmed transitional cell carcinoma of the genitourinary tract~ * Measurable disease as defined by RECIST version 1.1~Exclusion Criteria:~* Untreated or symptomatic central nervous system (CNS) metastases~* Impaired cardiac function or clinically significant cardiac disease~  - Treatment with any anticancer therapy or participation in another therapeutic clinical study with investigational drugs \</=14 days (\</=28 days for patients in Korea) prior to first dose of FPA144~* Ongoing acute adverse effects from prior anticancer or investigational therapy \> NCI CTCAE Grade 1~* Retinal disease or a history of retinal disease or detachment~* Corneal defects, corneal ulcerations, keratitis, keratoconus, history of corneal transplant, or other known abnormalities of the cornea~* Major surgical procedures are not allowed ≤28 days prior to FPA144 administration~* Females who are pregnant or breastfeeding; women of childbearing potential must not be considering getting pregnant during the study~  - Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study~* Known allergy or hypersensitivity to components of the FPA144 formulation including polysorbate~* History of prior malignancy except:~* a) Curatively treated non-melanoma skin cancer or~* b) Solid tumor treated curatively more than 5 years previously without evidence of recurrence or~* c) History of other malignancy that in the Investigator's opinion would not affect the determination of study treatment effect~* Prior treatment with any selective inhibitor (e.g., AZD4547, BGJ398, JNJ-42756493, BAY1179470) of the FGF-FGFR pathway

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1A: FPA144 Dose Escalation Solid Tumors (Type: EXPERIMENTAL): Dose escalation of FPA144 (0.3 mg/kg to 15 mg/kg)
- Part 1B: FPA144 Dose Escalation Gastric Cancer (Type: EXPERIMENTAL): Dose escalation of FPA144 (3-10 mg/kg) in patients with gastric cancer
- Part 2: FPA144 Dose Expansion Gastric or Other Solid Tumors (Type: EXPERIMENTAL): Evaluation of objective responses in patients with tumors with various levels of FGFR2b overexpression

Based on this trial design, predict the completion outcome and termination type (if applicable).